What it is
The team packaged anti-CD19 CAR mRNA into lipid nanoparticles targeted to CD8+ T cells, reprogramming the cells directly inside the body rather than extracting and engineering them ex vivo. A single in vivo dose controlled tumors in humanized mice and drove durable B-cell depletion in nonhuman primates. The B cells that returned afterward were predominantly naive, a signature consistent with an immune system reset.
Why it matters
Conventional CAR-T therapy needs weeks of bespoke manufacturing plus lymphodepleting chemotherapy, confining it to a handful of specialized centers. Generating CAR-T in vivo could turn cell therapy into an off-the-shelf injection usable far more widely and for autoimmune disease as well as cancer. The paper has already drawn 258 citations and sits at a field-weighted citation impact of roughly 123, reflecting how quickly the approach has been taken up.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underCAR-T, in vivo cell therapy, lipid nanoparticles, immunotherapy, mRNA